Stock BNTX BIONTECH SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
87.21 USD +0.58% Intraday chart for BioNTech SE +0.46% -17.37%
04-25 Sector Update: Health Care Stocks Drop in Afternoon Trading MT
04-25 GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,837 16,071 54,764 34,112 22,730 19,686 - -
Enterprise Value (EV) 1 6,318 14,964 53,372 20,449 22,730 5,710 6,041 7,406
P/E ratio -35.6 x 1,112 x 5.72 x 3.72 x 25 x -35.7 x -43.8 x -30.4 x
Yield - - - - - - - -
Capitalization / Revenue 63 x 33.3 x 2.89 x 1.97 x 5.95 x 7.04 x 7.21 x 7.09 x
EV / Revenue 58.2 x 31 x 2.81 x 1.18 x 5.95 x 2.04 x 2.21 x 2.67 x
EV / EBITDA -42.8 x -343 x 3.47 x 1.6 x 26 x -8.93 x -7.99 x -8.39 x
EV / FCF -26.6 x -188 x 72.5 x 1.55 x - 17.6 x -10.3 x -15 x
FCF Yield -3.75% -0.53% 1.38% 64.6% - 5.68% -9.68% -6.65%
Price to Book 13.9 x 11.8 x 4.62 x 1.7 x - 0.97 x 1 x 1.05 x
Nbr of stocks (in thousands) 226,262 240,786 241,521 243,019 237,716 240,990 - -
Reference price 2 30.22 66.74 226.7 140.4 95.62 81.69 81.69 81.69
Announcement Date 31/03/20 30/03/21 30/03/22 27/03/23 20/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 108.6 482.3 18,977 17,311 3,819 2,796 2,732 2,778
EBITDA 1 -147.6 -43.67 15,359 12,766 873.8 -639.5 -756.3 -882.7
EBIT 1 -181.5 -82.42 15,284 12,643 690.4 -871.5 -930.9 -1,007
Operating Margin -167.16% -17.09% 80.54% 73.03% 18.08% -31.17% -34.07% -36.25%
Earnings before Tax (EBT) 1 -179.4 -145.8 15,046 12,954 1,186 -726.7 -602.6 -637.5
Net income 1 -179.1 15.2 10,292 9,434 930.3 -551.6 -504 -636.1
Net margin -164.89% 3.15% 54.24% 54.5% 24.36% -19.73% -18.45% -22.9%
EPS 2 -0.8500 0.0600 39.63 37.77 3.830 -2.287 -1.867 -2.685
Free Cash Flow 1 -237.1 -79.51 735.7 13,214 - 324.4 -584.7 -492.2
FCF margin -218.37% -16.48% 3.88% 76.34% - 11.61% -21.4% -17.72%
FCF Conversion (EBITDA) - - 4.79% 103.51% - - - -
FCF Conversion (Net income) - - 7.15% 140.06% - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 31/03/20 30/03/21 30/03/22 27/03/23 20/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,087 5,532 6,375 3,196 3,461 4,278 1,277 167.7 895.3 1,479 453.1 158.2 705.5 1,464 97.2
EBITDA 1 4,743 4,726 - - 2,421 3,322 685.8 - 114.4 605 -585 -660 -290 824 -
EBIT 1 4,724 4,700 4,753 2,210 2,388 3,293 654.4 -563.3 73.1 526.2 -373.5 -637.5 -246 294.6 -803.7
Operating Margin 77.6% 84.95% 74.56% 69.13% 68.98% 76.97% 51.25% -335.9% 8.16% 35.58% -82.44% -402.95% -34.87% 20.13% -826.88%
Earnings before Tax (EBT) 1 4,667 4,714 5,018 2,319 2,444 3,173 707.7 -412.2 227.4 663.2 -289.8 -574.5 -193 428.4 -
Net income 1 3,211 3,166 3,699 1,672 1,785 2,279 502.2 -190.4 160.6 457.9 -263.7 -527.2 -178.3 398.3 -
Net margin 52.75% 57.23% 58.02% 52.31% 51.57% 53.26% 39.33% -113.54% 17.94% 30.96% -58.2% -333.25% -25.27% 27.21% -
EPS 2 12.35 12.18 14.24 6.450 6.980 9.260 2.050 -0.7900 0.6700 1.900 -1.195 -1.918 -0.6788 1.332 -1.504
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 09/11/21 30/03/22 09/05/22 08/08/22 07/11/22 27/03/23 08/05/23 07/08/23 06/11/23 20/03/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 519 1,107 1,391 13,663 - 13,977 13,645 12,280
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -237 -79.5 736 13,214 - 324 -585 -492
ROE (net income / shareholders' equity) -47.1% 1.63% 155% 59.1% - -1.46% -2.27% -3.54%
ROA (Net income/ Total Assets) -24.7% 0.98% 113% 48.2% - -1.69% -2.65% -3.75%
Assets 1 725.3 1,558 9,075 19,555 - 32,598 18,995 16,960
Book Value Per Share 2 2.180 5.680 49.00 82.50 - 84.30 81.90 77.50
Cash Flow per Share 2 -0.9400 -0.0500 3.430 55.80 - 2.070 -0.4100 1.400
Capex 1 38.6 66 128 329 - 435 349 327
Capex / Sales 35.54% 13.69% 0.67% 1.9% - 15.56% 12.77% 11.77%
Announcement Date 31/03/20 30/03/21 30/03/22 27/03/23 20/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
81.69 EUR
Average target price
106.6 EUR
Spread / Average Target
+30.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. Financials BioNTech SE